CervoMed Inc.
No SEC Form 4 filings for $CRVO in the last 30 days.
See all $CRVO insider activity →CervoMed published an investor presentation on its website under Regulation FD, covering business, clinical studies, development plans, and financial position. The presentation is for use in investor and analyst meetings and may be updated periodically. The information is not deemed filed for SEC liability purposes.
H.C. Wainwright reiterated a Buy rating and $25 price target on CervoMed (CRVO) following advances in its neflamapimod drug program. The stock trades at $3.02 with a $45.66M market cap, up 13% in the past week. The company announced a new 50mg tablet formulation for twice-daily dosing, FDA approval for higher doses, and controlled manufacturing processes. Analysts' price targets range from $7 to $25.
CervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CRVO (CervoMed Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CRVO coverage spans technology, financial news and regulation.
The filing adds modest new detail for analysts and investors.
The new formulation reduces dosing risk and supports larger-scale production, improving the drug's commercial prospects.
The formulation and regulatory update de‑risk the program and improve dosing flexibility, likely supporting upside in CRVO.
The regulatory and formulation advances reduce CMC risk and support a higher‑dose BID regimen, improving the drug's commercial prospects.
Positive early biomarker read‑out could boost investor confidence and drive short‑term price appreciation ahead of the conference.
AlphAI scores every news story that mentions CRVO with an AI model for sentiment and relevance, and aggregates insider trades from CervoMed Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CervoMed published an investor presentation on its website under Regulation FD, covering business, clinical studies, development plans, and financial position. The presentation is for use in investor and analyst meetings and may be updated periodically. The information is not deemed filed for SEC liability purposes.
1 min readH.C. Wainwright reiterated a Buy rating and $25 price target on CervoMed (CRVO) following advances in its neflamapimod drug program. The stock trades at $3.02 with a $45.66M market cap, up 13% in the past week. The company announced a new 50mg tablet formulation for twice-daily dosing, FDA approval for higher doses, and controlled manufacturing processes. Analysts' price targets range from $7 to $25.
2 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA
2 min readCervoMed (CRVO) announced a new 50 mg tablet formulation for neflamapimod, meeting Phase 1 study objectives. The FDA removed a plasma drug exposure limit. The company plans a 100 mg twice-daily regimen for future trials, aiming to increase trough concentrations. CRVO stock closed at $2.54, up 0.79%.
2 min readCervoMed Inc. (CRVO) announced that initial results from its Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA) will be presented at the ISFTD Annual Meeting. The trial, involving 25 participants, aims to evaluate the safety and efficacy of neflamapimod, a drug targeting neuroinflammation and synaptic dysfunction. NfvPPA, a type of frontotemporal dementia, currently has no approved treatments in the U.S. or E.U.
2 min readCervoMed Inc. (CRVO) announced that its drug candidate, neflamapimod, received an Innovation Passport from the UK's ILAP for treating Dementia with Lewy Bodies (DLB). This designation accelerates regulatory review and market access in the UK, validating the drug's potential. The company is seeking a partner for Phase 3 trials and expects interim data from other trials in late 2026.
2 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation und
6 min readCervoMed Inc. (NASDAQ: CRVO) reported at AAIC 2026 new Phase 2b analyses for neflamapimod in dementia with Lewy bodies. The company said results support selecting 50 mg TID for a planned Phase 3, citing effects on CDR-SB, plasma pTau181 exposure, and MRI basal forebrain atrophy/connectivity. It also reported Phase 2 data for 80 mg BID meeting safety and PK objectives.
6 min readCervoMed (NASDAQ: CRVO) said it completed enrollment in a Phase 2a trial of oral p38a inhibitor neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study enrolled 25 patients and includes 24 weeks of dosing plus a 12-week randomized placebo-controlled extension. Interim biomarker data are slated for CTAD in Nov 2026, with first biomarker and clinical data expected Q4 2026 and Q1 2027.
2 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ex_978640.htm EXHIBIT 4.1 ex_978640.htm Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FR
3 min read
